open access

Vol 21, No 2 (2014)
Original articles
Submitted: 2013-05-06
Accepted: 2013-06-09
Published online: 2014-04-15
Get Citation

Epidemiology, anticoagulant treatment and risk of thromboembolism in patients with valvular atrial fibrillation: Results from Atrial Fibrillation in Turkey: Epidemiologic Registry (AFTER)

Hasan Kaya, Faruk Ertaş, Zekeriya Kaya, Nihan Kahya Eren, Murat Yüksel, Bayram Köroğlu, Nuri Köse, Abdulkadir Yıldız, Tolga Çimen, Mehmet Sıddık Ülgen
DOI: 10.5603/CJ.a2013.0085
·
Cardiol J 2014;21(2):158-162.

open access

Vol 21, No 2 (2014)
Original articles
Submitted: 2013-05-06
Accepted: 2013-06-09
Published online: 2014-04-15

Abstract

Background: The aim of this study was to perform a multicenter, prospective investigation regarding the epidemiology, the current effectiveness of therapeutic anticoagulation, and the risk of thromboembolism in patients with valvular atrial fibrillation (AF) based on the records of the Atrial Fibrillation in Turkey: Epidemiologic Registry (AFTER) study.

Methods: Patients were selected from a total of 2,242 consecutive admissions that presented with AF diagnosed via electrocardiogram. Those diagnosed with non-valvular AF were excluded from the AFTER study population, which left 497 patients with valvular AF for analysis.

Results: The etiology of valvular AF in patients was either attributed to rheumatic mitral valve stenosis (n = 217) or possessing a prosthetic heart valve (n = 280). Out of all the patients with valvular AF, 83.1% were taking warfarin for anticoagulation. Only 36.1% demonstrated a therapeutic international normalized ratio (INR), and among those patients it was found that 19.1% exhibited a labile INR. Multivariate analysis revealed that age was the only independent predictor of thromboembolic events in patients with valvular AF.

Conclusions: Many valvular AF patients are not maintained at therapeutic INR levels, which poses a threat to patient health as they age and are at greater risk for thromboembolism.

Abstract

Background: The aim of this study was to perform a multicenter, prospective investigation regarding the epidemiology, the current effectiveness of therapeutic anticoagulation, and the risk of thromboembolism in patients with valvular atrial fibrillation (AF) based on the records of the Atrial Fibrillation in Turkey: Epidemiologic Registry (AFTER) study.

Methods: Patients were selected from a total of 2,242 consecutive admissions that presented with AF diagnosed via electrocardiogram. Those diagnosed with non-valvular AF were excluded from the AFTER study population, which left 497 patients with valvular AF for analysis.

Results: The etiology of valvular AF in patients was either attributed to rheumatic mitral valve stenosis (n = 217) or possessing a prosthetic heart valve (n = 280). Out of all the patients with valvular AF, 83.1% were taking warfarin for anticoagulation. Only 36.1% demonstrated a therapeutic international normalized ratio (INR), and among those patients it was found that 19.1% exhibited a labile INR. Multivariate analysis revealed that age was the only independent predictor of thromboembolic events in patients with valvular AF.

Conclusions: Many valvular AF patients are not maintained at therapeutic INR levels, which poses a threat to patient health as they age and are at greater risk for thromboembolism.

Get Citation

Keywords

atrial fibrillation, valvular, predictor, anticoagulant treatment

About this article
Title

Epidemiology, anticoagulant treatment and risk of thromboembolism in patients with valvular atrial fibrillation: Results from Atrial Fibrillation in Turkey: Epidemiologic Registry (AFTER)

Journal

Cardiology Journal

Issue

Vol 21, No 2 (2014)

Pages

158-162

Published online

2014-04-15

Page views

2345

Article views/downloads

1500

DOI

10.5603/CJ.a2013.0085

Bibliographic record

Cardiol J 2014;21(2):158-162.

Keywords

atrial fibrillation
valvular
predictor
anticoagulant treatment

Authors

Hasan Kaya
Faruk Ertaş
Zekeriya Kaya
Nihan Kahya Eren
Murat Yüksel
Bayram Köroğlu
Nuri Köse
Abdulkadir Yıldız
Tolga Çimen
Mehmet Sıddık Ülgen

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl